At ENDO 2026, Aoife M. Egan framed a rising clinical challenge: type 2 diabetes is increasingly diagnosed in people of childbearing age. She explained that younger-onset disease often presents a more aggressive course and can progress rapidly to complications without timely intervention. The article reported that the prevalence of pregestational diabetes has increased in recent years; the author cited U.K. audit trends and referenced a 2021 estimate that 10.9 of 1,000 births were complicated by preexisting diabetes, representing a marked rise from earlier years. Obesity, declining physical activity, and greater consumption of highly processed foods were listed as major contributors. Maternal age trends were also raised as a factor that increases the likelihood of chronic disease before pregnancy.
Egan warned of a potential transgenerational effect: data are emerging that offspring of mothers with any form of diabetes in pregnancy have increased lifetime risk of type 2 diabetes. The report emphasized that the population groups experiencing the largest increases are often those with the least access to care. The source noted socioeconomic, health literacy, and ethnic disparities that limit access to effective prevention measures, bariatric surgery, or pharmacotherapy because of coverage and cost barriers. Clinicians at the session were urged to consider these social determinants when designing care pathways.
Egan described three concrete gaps in current practice. First, most people with type 2 diabetes do not receive preconception counseling or care; the source asserted that routine screening for pregnancy intent at primary visits and offering contraception or preconception planning when appropriate should be standard practice. In an ideal pathway, a patient-centered preconception visit includes medication review, counseling on nutrition and activity, optimization of glycemic control, and screening for diabetes complications and infectious diseases.
Second, medication management proved a recurring concern. The source pointed out that many newer glucose-lowering agents (for example, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors) lack robust pregnancy-safety data, and people often become pregnant while taking these agents. That scenario forces rapid therapeutic change in early pregnancy—commonly to insulin or, in selected cases, metformin—which carries risks of glycemic destabilization and rebound weight change if not managed in a planned way. The author reported Egan’s recommendation to transition off uncertain agents in a controlled preconception setting when possible; the article did not provide specific dosing regimens or protocolized switch strategies because those were not reported in the source presentation.
Third, fragmentation of care drives missed opportunities across the continuum. The session highlighted failures in handoffs between obstetrics, maternal-fetal medicine, endocrinology, and primary care. The source described real-world barriers: missed appointments, return-to-work pressures postpartum, and lack of direct inter-specialty communication. Practical steps recommended by Egan included documenting a postpartum diabetes plan in the electronic medical record, confirming the receiving clinician who will assume care, and directly communicating follow-up recommendations to that clinician. For patients at elevated risk of being lost to follow-up, the presenter suggested a designated healthcare worker to help navigate appointments and resources; the article noted that virtual care models may expand reach, especially for those juggling childcare and work obligations.
The session prompted robust audience engagement, the author reported, with clinicians seeking guidance on medication choices and longitudinal follow-up strategies. Egan and the article recommended clinicians consult the joint Endocrine Society and European Society of Endocrinology guideline titled "Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline" for detailed recommendations on medication use during pregnancy; the guideline was published in 2025 and was cited as a clinical resource used in the presentation.
Egan urged clinicians to pursue individualized, patient-centered approaches to improve outcomes and to focus efforts on populations most likely to be underserved. The source emphasized that, while many women with type 2 diabetes can have positive pregnancy outcomes, systemic barriers must be addressed.
The article closed on specific, unresolved issues documented in the source: the evidence base for the safety of newer glucose-lowering agents in pregnancy remains limited, and the source did not report new trial data to fill that gap. The other outstanding challenge is operational: the article did not provide tested metrics or implementation data for the proposed care-navigation and virtual-care models, leaving unanswered questions about which systems-based interventions most reliably improve postpartum follow-up and long-term metabolic outcomes.